Compare Salesforce Inc (CRM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Zimmer Biomet Holdings Inc — how do they compare? Salesforce Inc trades at $167.14 (market cap $137.23B), while Zimmer Biomet Holdings Inc trades at $90.17 (market cap $17.61B). The key difference: Salesforce Inc is far larger — about 7.8× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Salesforce Inc nearer its low. Which is the better fit depends on your goals.
| CRM | ZBH | |
|---|---|---|
Market Cap | $137.23B | $17.61B |
Sector | Technology | Health |
52-Week High | $270.25 | $107.71 |
52-Week Low | $150.12 | $79.58 |
Enterprise Value | $167.28B | $24.66B |
Dividend Yield | 1.05% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $167.00, down 2.46% amid broader tech sector volatility. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected) and robust profitability (net margin of 18.73%). Technical indicators are neutral with support at $165 and resistance at $171. Recent news highlights AI-driven growth potential but also sector-wide pressure from inflation concerns and competitive AI advancements.
Outlook remains positive due to solid financials and analyst consensus ($235.90 price target), though risks include tech sector volatility and execution challenges in AI monetization. The current valuation (P/E 19.42) offers a reasonable entry point for long-term investors focused on CRM's rule-of-44 performance and expanding free cash flow.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
